Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986258 alone and with nivolumab in advanced malignant tumors
NCT03446040Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2018
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of BMS-986258 in renal cell carcinoma (RCC), colorectal cancer (CRC), non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (HNSCC), triple-negative breast cancer (TNBC), sponsored by Bristol Myers Squibb. Started Mar 2018; status: terminated.
02
Drugs
BMS-986258
03
Conditions
renal cell carcinoma (RCC)colorectal cancer (CRC)non-small cell lung cancer (NSCLC)squamous cell carcinoma of the head and neck (HNSCC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03446040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03446040.